Protalix Biotherapeutics Financials
| PLX Stock | USD 1.66 0.03 1.78% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | 1.536 |
|
|
The essential information of the day-to-day investment outlook for Protalix Biotherapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Protalix Biotherapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Protalix Biotherapeutics.
Cash And Equivalents |
|
Protalix | Select Account or Indicator |
Understanding current and past Protalix Biotherapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Protalix Biotherapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Protalix Biotherapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Protalix Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Protalix Biotherapeutics. Check Protalix Biotherapeutics' Beneish M Score to see the likelihood of Protalix Biotherapeutics' management manipulating its earnings.
Protalix Biotherapeutics Stock Summary
Protalix Biotherapeutics competes with Corvus Pharmaceuticals, Aldeyra, Checkpoint Therapeutics, Cidara Therapeutics, and Akebia Ther. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company was founded in 1993 and is based in Hackensack, New Jersey. Protalix Biotherapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 202 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NYSE MKT Exchange |
| ISIN | US74365A3095 |
| CUSIP | 74365A309 74365A101 68750Q101 |
| Location | Israel |
| Business Address | Science Park, Karmiel, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.protalix.com |
| Phone | 972 4 902 8100 |
| Currency | USD - US Dollar |
Protalix Biotherapeutics Key Financial Ratios
| Return On Equity | -0.43 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.18) % | ||||
| Price To Sales | 3.27 X | ||||
| Revenue | 65.49 M |
Protalix Biotherapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 45.4M | 67.9M | 73.7M | 55.8M | 84.4M | 51.0M | |
| Other Current Liab | 11.9M | 13.9M | 15.2M | 10.6M | 15.3M | 16.0M | |
| Net Debt | 43.1M | 46.1M | (5.5M) | 16.4M | 2.6M | 2.8M | |
| Cash | 17.8M | 18.3M | 39.0M | 17.1M | 23.6M | 31.8M | |
| Net Receivables | 4.7M | 2M | 3.4M | 4.6M | 5.3M | 3.1M | |
| Other Current Assets | 698K | 2.1M | 1.3M | 1.3M | 1.1M | 1.6M | |
| Total Liab | 115.7M | 95.0M | 79.7M | 66.4M | 50.9M | 56.1M | |
| Total Current Assets | 32.5M | 55.7M | 61.7M | 44.9M | 69.9M | 42.5M | |
| Retained Earnings | (340.8M) | (347.4M) | (374.9M) | (389.9M) | (381.5M) | (362.5M) | |
| Short Term Debt | 5.4M | 59.9M | 2.4M | 2.2M | 23.1M | 18.6M | |
| Common Stock | 15K | 35K | 46K | 54K | 73K | 62.8K | |
| Accounts Payable | 6.5M | 7.2M | 7.0M | 5.9M | 4.3M | 4.3M | |
| Other Assets | 2.0M | 7.4K | 2.1M | 1.3M | 1.0 | 0.95 | |
| Other Liab | 20.1M | 4.0M | 14.3M | 1.6M | 1.5M | 1.4M | |
| Inventory | 8.2M | 13.1M | 18.0M | 16.8M | 19.0M | 9.6M | |
| Net Tangible Assets | (70.3M) | (27.0M) | (6.0M) | (10.6M) | (9.6M) | (10.1M) | |
| Long Term Debt | 51.0M | 51K | 27.9M | 28.2M | 25.4M | 28.8M | |
| Capital Surpluse | 270.5M | 320.3M | 368.9M | 379.2M | 436.0M | 272.0M | |
| Long Term Debt Total | 51.5M | 51K | 27.9M | 28.2M | 25.4M | 28.3M | |
| Net Invested Capital | (15.1M) | 31.5M | 21.9M | 17.5M | 53.8M | 56.5M |
Protalix Biotherapeutics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 8.0M | 9.7M | 7.5M | 2.5M | 3.2M | 2.8M | |
| Operating Income | (10.7M) | 1.8M | (20.5M) | (13.0M) | 10.5M | 11.0M | |
| Ebit | (10.7M) | 3.1M | (20.1M) | (11.9M) | 10.5M | 11.0M | |
| Ebitda | (8.7M) | 4.5M | (18.9M) | (10.8M) | 11.7M | 12.2M | |
| Income Before Tax | (18.3M) | (6.5M) | (27.6M) | (14.4M) | 8.6M | 9.0M | |
| Net Income | (26.2M) | (14.9M) | (34.0M) | (14.9M) | 8.3M | 8.7M | |
| Income Tax Expense | 8.0M | 8.4M | 6.4M | 530K | 254K | 241.3K | |
| Total Revenue | 54.7M | 62.9M | 38.4M | 47.6M | 65.5M | 68.8M | |
| Gross Profit | 43.8M | 52.0M | 22.0M | 28.0M | 42.5M | 44.6M | |
| Cost Of Revenue | 10.9M | 10.9M | 16.3M | 19.6M | 23.0M | 24.1M | |
| Research Development | 44.6M | 38.2M | 29.7M | 29.3M | 17.1M | 28.1M | |
| Net Interest Income | (7.6M) | (9.2M) | (7.1M) | (1.4M) | (1.9M) | (2.0M) | |
| Interest Income | 407K | 438K | 401K | 1.1M | 1.3M | 686.3K |
Protalix Biotherapeutics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Protalix Biotherapeutics. It measures of how well Protalix is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Protalix Biotherapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Protalix had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Protalix Biotherapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (20.0M) | 473K | 20.7M | (21.9M) | 6.5M | 6.8M | |
| Free Cash Flow | (20.0M) | (26.8M) | (11.7M) | (25.6M) | (2.5M) | (2.6M) | |
| Other Non Cash Items | 3.4M | 3.6M | 3.1M | (1.2M) | (638.0K) | (606.1K) | |
| Capital Expenditures | 627K | 655K | 1.5M | 628K | 1.1M | 1.5M | |
| Net Income | (18.3M) | (6.5M) | (27.6M) | (14.9M) | 8.3M | 8.7M | |
| End Period Cash Flow | 17.8M | 18.3M | 39.0M | 17.1M | 23.6M | 31.8M | |
| Depreciation | 1.6M | 1.3M | 1.1M | 1.1M | 1.2M | 2.0M | |
| Change To Inventory | 414K | (4.9M) | (4.9M) | 1.2M | (2.2M) | (2.4M) | |
| Change To Netincome | 835K | 2.8M | 3.6M | 556K | 639.4K | 607.4K | |
| Net Borrowings | (1.4M) | (4.8M) | (215K) | (34.1M) | (30.7M) | (29.2M) | |
| Investments | (883K) | (20M) | 18.9M | (5.0M) | (16.7M) | (15.9M) |
Protalix Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Protalix Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Protalix Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Protalix Biotherapeutics competition to find correlations between indicators driving Protalix Biotherapeutics's intrinsic value. More Info.Protalix Biotherapeutics is regarded fourth in return on equity category among its peers. It also is regarded fourth in return on asset category among its peers . At this time, Protalix Biotherapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Protalix Biotherapeutics' earnings, one of the primary drivers of an investment's value.Protalix Biotherapeutics Systematic Risk
Protalix Biotherapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Protalix Biotherapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Protalix Biotherapeutics correlated with the market. If Beta is less than 0 Protalix Biotherapeutics generally moves in the opposite direction as compared to the market. If Protalix Biotherapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Protalix Biotherapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Protalix Biotherapeutics is generally in the same direction as the market. If Beta > 1 Protalix Biotherapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Protalix Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Protalix Biotherapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Protalix Biotherapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Protalix Biotherapeutics November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Protalix Biotherapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Protalix Biotherapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Protalix Biotherapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Protalix Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Protalix Biotherapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.42 | |||
| Information Ratio | 0.1899 | |||
| Maximum Drawdown | 20.38 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 10.0 |
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.